Verrica Pharmaceuticals (VRCA) Metrics: History & Chart

Verrica Pharmaceuticals Inc.(VRCA)

Biotechnology · West Chester, PA

$4.21-0.10 (-2.32%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

West Chester, PA

76 employees

www.verrica.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jayson Rieger

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-6.30%
30D Total Return	-18.68%
YTD Total Return	-48.13%
1Y Total Return	-7.71%
3Y Total Return	-89.06%
5Y Total Return	-96.44%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-48.13%
2025	+18.71%
2024	-90.44%
2023	+166.18%
2022	-69.98%
2021	-20.42%
2020

CAGR TTM	-7.67%
CAGR 3Y	-52.17%
CAGR 5Y	-48.68%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

VRCA Valuation Metrics

VRCA Stock Price Metrics

VRCA Dividend Metrics

VRCA Growth Rate Metrics

VRCA Discounted Cash Flow Metrics

VRCA Returns By Period

VRCA Yearly Returns

VRCA Average Annual Returns By Period (CAGR)

VRCA Revenue Metrics

VRCA PE Ratio Metrics

VRCA PS Ratio Metrics

VRCA PB Ratio Metrics

VRCA Price to Free Cash Flow Ratio Metrics

VRCA Debt to Equity Ratio Metrics

VRCA PEG Ratio Metrics

VRCA FCF Yield

VRCA Earnings Yield

VRCA EBITDA Yield

VRCA OCF Yield

VRCA EV/EBIT Ratio Metrics

VRCA EV/EBITDA Ratio Metrics

VRCA EV/Assets Ratio Metrics

VRCA EV/Sales Ratio Metrics

VRCA Current Ratio Metrics

VRCA Quick Ratio Metrics

VRCA ROIC Metrics

VRCA Return on Assets Metrics

VRCA Return on Equity Metrics

VRCA Net Profit Margin Metrics

VRCA Gross Profit Margin Metrics

VRCA Tax Rate Metrics

PS Ratio	3.03
PS Ratio Avg TTM	2.63
PS Ratio Avg 3Y	11.40
Current VS TTM Avg	+15.33%
Current VS 3Y Avg	-73.42%
Current VS 5Y Avg	-84.16%

PB Ratio	21.32
PB Ratio Avg TTM	10.91
PB Ratio Avg 3Y	9.53
Current VS TTM Avg	+95.41%
Current VS 3Y Avg	+123.72%
Current VS 5Y Avg	+302.84%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.42
Debt/Equity Ratio Avg TTM	(0.75)
Debt/Equity Ratio Avg 3Y	(1.02)
Current VS TTM Avg	+156.10%
Current VS 3Y Avg	+141.37%
Current VS 5Y Avg	+287.74%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	2.29
Ev/Assets Ratio Avg TTM	2.00
Ev/Assets Ratio Avg 3Y	1.95
Current VS TTM Avg	+14.61%
Current VS 3Y Avg	+17.56%
Current VS 5Y Avg	+3.28%

Ev/Sales Ratio	2.72
Ev/Sales Ratio Avg TTM	2.74
Ev/Sales Ratio Avg 3Y	12.40
Current VS TTM Avg	-0.75%
Current VS 3Y Avg	-78.06%
Current VS 5Y Avg	-84.66%

Current Ratio	1.45
Current Ratio Avg TTM	1.72
Current Ratio Avg 3Y	2.10
Current VS TTM Avg	-15.20%
Current VS 3Y Avg	-30.76%
Current VS 5Y Avg	-37.19%

Quick Ratio	1.33
Quick Ratio Avg TTM	1.61
Quick Ratio Avg 3Y	2.00
Current VS TTM Avg	-16.97%
Current VS 3Y Avg	-33.16%
Current VS 5Y Avg	-40.62%

ROIC	(207.23%)
ROIC Avg 3Y	(129.22%)
ROIC Avg 5Y	(95.91%)
Current VS 3Y Avg	-60.37%
Current VS 5Y Avg	-116.05%
Current VS 10Y Avg	-370.78%

ROA	(86.58%)
ROA Avg TTM	(15.75%)
ROA Avg 3Y	(22.40%)
Current VS TTM Avg	-449.64%
Current VS 3Y Avg	-286.44%
Current VS 5Y Avg	-384.15%

ROE	(724.01%)
ROE Avg TTM	(302.44%)
ROE Avg 3Y	(233.80%)
Current VS TTM Avg	-139.39%
Current VS 3Y Avg	-209.67%
Current VS 5Y Avg	-630.98%

Net Profit Margin	(102.84%)
Net Profit Margin Avg TTM	(115.20%)
Net Profit Margin Avg 3Y	(381.10%)
Current VS TTM Avg	+10.73%
Current VS 3Y Avg	+73.02%
Current VS 5Y Avg	+86.73%

Gross Profit Margin	85.89%
Gross Pft Margin Avg TTM	85.64%
Gross Pft Margin Avg 3Y	89.51%
Current VS TTM Avg	+0.29%
Current VS 3Y Avg	-4.05%
Current VS 5Y Avg	+84.17%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A